register_number stringlengths 11 11 | secondary_id listlengths 1 10 | url stringlengths 44 44 | brief_title stringlengths 20 290 | brief_summary stringlengths 63 5.05k | official_title stringlengths 25 483 โ | intervention listlengths 1 19 | arm_intervention listlengths 1 21 โ | f_condition listlengths 1 135 | sponsor listlengths 1 1 | collaborator listlengths 1 25 | experimental_drug listlengths 1 13 | study_identifier listlengths 1 7 โ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NCT00115297 | [
{
"id_field": "org_study_id",
"id_value": [
"192"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01HL080073"
]
}
] | https://clinicaltrials.gov/study/NCT00115297 | Montelukast for Early Life Wheezing | This study will determine the effects of montelukast on the duration of wheezing in children 12 months to 3 years of age who visit a physician for care of a wheezing illness. Only patients from the Ankara area of Hacettepe University Medical Center in Turkey will be included in this study. | Effects of Montelukast on Early Life Wheezing | [
{
"description": "Participants who are 2 to 3 years old received 5-mg montelukast tablets and participants who are 12 months to 2 years old received 4-mg montelukast granules.",
"name": "Montelukast",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "... | [
{
"design_group_description": "Participants who are 2 to 3 years old received 5-mg montelukast tablets and participants who are 12 months to 2 years old received 4-mg montelukast granules.",
"design_group_title": "Montelukast",
"design_group_type": "Experimental",
"design_group_type_normalized_id": ... | [
"Lung Diseases",
"Asthma"
] | [
"University of Massachusetts"
] | [
"National Heart, Lung & Blood Institute"
] | [
[
{
"name": "ๅญ้ฒๅธ็น้ ",
"lang": "CN"
},
{
"name": "Montelukast sodium",
"lang": "EN"
},
{
"name": "ใขใณใใซใซในใใใใชใฆใ ",
"lang": "JP"
}
]
] | null |
NCT03962283 | [
{
"id_field": "org_study_id",
"id_value": [
"MISO RF"
]
}
] | https://clinicaltrials.gov/study/NCT03962283 | Rifaximin and Misoprostol Combination Therapy for Healing of Small Bowel Ulcers in Aspirin Users | Background: Investigators have previously shown that misoprostol can heal small bowel ulcers in aspirin users with small bowel bleeding. However, the rate of small-bowel mucosal healing was low with use of misoprostol alone. There is evidence to suggest that bacteria contribute to the development aspirin-induced ulcers... | Rifaximin and Misoprostol Combination Therapy for Healing of Small Bowel Ulcers in Aspirin Users With Small Bowel Bleeding: A Double Blind Randomized Trial | [
{
"description": "Rifaximin 200mcg four times daily",
"name": "Rifaximin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Placebo Rifaximin four times daily",
"name": "Placebo oral tablet",
"normalized_type": "3d1aa88261d64c038413723970f2b5... | [
{
"design_group_description": "ASA daily + misoprostol + Rifaximin (Rifaximin group)",
"design_group_title": "Rifaximin",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description":... | [
"Small Bowel Disease",
"Rifaximin"
] | [
"The Chinese University of Hong Kong"
] | [
"Beijing Friendship Hospital"
] | [
[
{
"name": "ๅฉ็ฆๆๆ",
"lang": "CN"
},
{
"name": "Rifaximin",
"lang": "EN"
},
{
"name": "ใชใใกใญใทใใณ",
"lang": "JP"
}
]
] | null |
NCT05660746 | [
{
"id_field": "org_study_id",
"id_value": [
"2022-0071"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01DK132408-01"
]
},
{
"id_field": "acronym",
"id_value": [
"REMODEL-CD"
]
}
] | https://clinicaltrials.gov/study/NCT05660746 | Precise Infliximab Exposure and Pharmacodynamic Control | Approximately 3 million people in the United States are living with inflammatory bowel disease, which includes Crohn's Disease (CD). There are limited treatment options approved for use in children and adults with Crohn's disease. Physicians need better ways to inform decisions on treatment.<br/>The main reason for thi... | Precise Infliximab Exposure and Pharmacodynamic Control to Achieve Deep Remission in Pediatric Crohn's Disease | [
{
"description": "The RoadMAB Dashboard is a real-time decision support system that incorporates PK model-informed Bayesian estimation to provide precision dosing at the point of care.",
"name": "RoadMAB",
"normalized_type": "63bce838d71c4229808b289e8cf3172d",
"type": "Device"
},
{
"descript... | [
{
"design_group_description": "Induction Phase: 5-7.5 mg/kg at 0, 2, and 6 weeks. Maintenance Phase : 5-10 mg/kg at every 4-8 weeks based on results of drug concentration monitoring for a flat target of 5-10 ฮผg/mL.",
"design_group_title": "Conventional dosing",
"design_group_type": "Active Comparator",
... | [
"Crohn Disease"
] | [
"Cincinnati Children's Hospital Medical Center"
] | [
"National Institute of Diabetes & Digestive & Kidney Diseases",
"Janssen Scientific Affairs LLC"
] | [
[
{
"name": "่ฑๅคซๅฉ่ฅฟๅๆ",
"lang": "CN"
},
{
"name": "Infliximab",
"lang": "EN"
},
{
"name": "ใคใณใใชใญใทใใ๏ผ้บไผๅญ็ตๆใ๏ผ",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "REMODEL-CD"
}
] |
NCT00310791 | [
{
"id_field": "org_study_id",
"id_value": [
"Anorexia04"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01HD043869"
]
},
{
"id_field": "nct_alias",
"id_value": [
"NCT01343771"
]
}
] | https://clinicaltrials.gov/study/NCT00310791 | Adrenal and Gonadal Hormone Replacement in Anorexia Nervosa | This study seeks to gain new information on why young women with anorexia nervosa are predisposed to early bone loss and osteoporosis. Through a randomized treatment trial in which participants will receive either combined therapy with the adrenal hormone, dehydroepiandrosterone (DHEA) and estrogen replacement therapy ... | Effects of Adrenal and Gonadal Hormone Replacement in Young Women With Anorexia Nervosa | [
{
"description": "Hormone replacement therapy (estrogen/progestin). 0.3 mg conjugated estrogens x 3 months, followed by 9 months of oral contraceptive (20 mg ethinyl estradiol + 0.1 mg levonorgestrel)",
"name": "Hormone replacement therapy (estrogen/progestin)",
"normalized_type": "3d1aa88261d64c0384137... | [
{
"design_group_description": "Placebo (sugar pill); identical to treatment medication capsule",
"design_group_title": "Sugar Pill",
"design_group_type": "Placebo Comparator",
"design_group_type_normalized_id": "20d1ebb7d90a3d9b81daa54f73163ecb",
"intervention": [
{
"intervention_d... | [
"Anorexia Nervosa"
] | [
"The Children's Hospital Corp."
] | [
"Defense Language Institute Foreign Language Center",
"National Institute of Child Health & Human Development"
] | [
[
{
"name": "ๆฎๆ็พ้
ฎ",
"lang": "CN"
},
{
"name": "Prasterone",
"lang": "EN"
}
]
] | null |
NCT00781898 | [
{
"id_field": "org_study_id",
"id_value": [
"808422"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01DA024553"
]
}
] | https://clinicaltrials.gov/study/NCT00781898 | Treatment Study Using Depot Naltrexone (1/6) Philadelphia Coord/Data Mgmt Site | The aim of this project is to conduct a multi-site effectiveness study to determine whether the addition of a monthly injection of depot naltrexone to treatment as usual (TAU) will significantly improve outcome in parolees and probationers with a history of opioid addiction compared to TAU alone. Participants will be r... | Prevention of Relapse to Opioid Addiction Using Depot Naltrexone | [
{
"description": "Vivitrolยฎ extended release naltrexone 380 mg per month delivered in monthly intramuscular injections.",
"name": "Depot naltrexone",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Treatment as Usual (TAU) community treatment provid... | [
{
"design_group_title": "Depot Naltrexone",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": "Vivitrolยฎ extended release naltrexone 380 mg per month delivered in monthly intr... | [
"Opiate Addiction"
] | [
"University of Pennsylvania"
] | [
"National Institute on Drug Abuse"
] | [
[
{
"name": "็้
ธ็บณๆฒ้
ฎ",
"lang": "CN"
},
{
"name": "Naltrexone Hydrochloride",
"lang": "EN"
}
]
] | null |
NCT01936844 | [
{
"id_field": "org_study_id",
"id_value": [
"VCU HM15347"
]
}
] | https://clinicaltrials.gov/study/NCT01936844 | Interleukin (IL)-1 Blockade in Acute Heart Failure (Anakinra ADHF) | Anakinra ADHF is a double-blind randomized clinical trial of anakinra, recombinant human interleukin-1 receptor blocker, or placebo in patients with acute decompensated heart failure with the aim to quench the acute inflammatory response, as measured by the area-under-the-curve for C reactive protein over 14 days. | Interleukin-1 Blockade in Acute Decompensated Heart Failure | [
{
"description": "Anakinra 100 mg daily twice daily for days 1, 2, and 3",
"name": "Anakinra (high dose)",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Anakinra 100 mg daily for days 4-14",
"name": "Anakinra (standard dose)",
"normalized_... | [
{
"design_group_description": "Anakinra 100 mg twice daily for the first 3 days followed by 100 mg daily for days 4-14",
"design_group_title": "Anakinra (short)",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{... | [
"Heart Failure"
] | [
"Virginia Commonwealth University"
] | [
"American Heart Association, Inc."
] | [
[
{
"name": "ๅฎ็บณ็ฝไป็ด ",
"lang": "CN"
},
{
"name": "Anakinra (Amgen)",
"lang": "EN"
}
]
] | null |
NCT05463484 | [
{
"id_field": "org_study_id",
"id_value": [
"02-2021"
]
}
] | https://clinicaltrials.gov/study/NCT05463484 | Effects of a Composition on the Oral Microbiome, pH, Nitrite/Nitrate Ratio, Elastases and Inflammation in Oral Dysbiosis | Dysbiosis is a condition in which the normal function of an ecological net is altered. In dysbiosis a state of inflammation, a loss of hydration, a change in pH, a loss of the barrier function are all allies of key pathogens that initiate invasion and cytokine and pro-inflammatory mediators release that target other ti... | Effects of a Composition Delivered Via Toothpaste on the Oral Microbiome, pH, Nitrite/Nitrate Ratio, Elastases, and Inflammation in Patients With Oral Dysbiosis: A Controlled, Randomized, Double-blind Study. Part of Stop Dysbiosis Project | [
{
"description": "Fluoridated toothpaste with Saliactiveยฎ.",
"name": "Test composition Saliactiveยฎ (olive product, betaine and xylitol)",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Saliactiveยฎ"
],
"type": "Drug"
},
{
"description": "Fluoridated toot... | [
{
"design_group_description": "Toothpaste including an olive product, betaine and xylitol (Saliactiveยฎ).",
"design_group_title": "Test product",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"interven... | [
"Oral Dysbiosis"
] | [
"Mucosa Innovations, S.L."
] | [
"University of Granada"
] | [
[
{
"name": "ไธ้
ธๆฐๆฟๅกๆพ/ๆ่้
ธๆฒ็พ็น็ฝ",
"lang": "CN"
},
{
"name": "Fluticasone propionate/Salmeterol xinafoate",
"lang": "EN"
},
{
"name": "ใตใซใกใใญใผใซใญใทใใ้
ธๅกฉ/ใใซใใซใพใณใใญใใชใณ้
ธใจในใใซ",
"lang": "JP"
}
]
] | null |
NCT00490854 | [
{
"id_field": "org_study_id",
"id_value": [
"10513"
]
},
{
"id_field": "secondary_id",
"id_value": [
"H7U-JE-IDBF"
]
}
] | https://clinicaltrials.gov/study/NCT00490854 | A Study for Patients With Type 2 Diabetes Mellitus | The purpose of the study is to compare the human insulin inhalation powder plus oral anti-hyperglycemic medication with injected insulin (neutral protamine hegedom insulin) plus oral anti-hyperglycemic medication on lowering the blood sugar level. | A Crossover Study to Evaluate the Efficacy and Safety of Preprandial Human Insulin Inhalation Powder (HIIP) Compared to Once-Daily NPH in Insulin-Naรฏve Patients With Type 2 Diabetes Mellitus on Oral Agents | [
{
"description": "patient specific, inhaled, at meals, 76 weeks",
"name": "Human Insulin Inhalation Powder",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"LY 041001"
],
"type": "Drug"
},
{
"description": "patient specific dose, injected, daily, 76 week... | [
{
"design_group_title": "1",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "patient specific dose, injected, daily, 76 weeks",
"intervention_name": "Neutral protamine h... | [
"Diabetes Mellitus, Type 2"
] | [
"Eli Lilly & Co."
] | [
"Alkermes, Inc."
] | [
[
{
"name": "ไบบ่ฐๅฒ็ด ๏ผ่ฏบๅ่ฏบๅพท๏ผ",
"lang": "CN"
},
{
"name": "Insulin human (rDNA origin, Novo Nordisk)",
"lang": "EN"
},
{
"name": "ใคใณในใชใณ ใใ๏ผ้บไผๅญ็ตๆใ๏ผ",
"lang": "JP"
}
]
] | null |
NCT00713167 | [
{
"id_field": "org_study_id",
"id_value": [
"SBMU 87-01-106-5694"
]
},
{
"id_field": "acronym",
"id_value": [
"GSE"
]
}
] | https://clinicaltrials.gov/study/NCT00713167 | The Efficacy of Red Grape Seed Extract on Lipid Profile and Oxidized Low-Density Lipoprotein (OX-LDL) | Antioxidants are potent scavengers of free radicals and serve as inhibitors of neoplastic processes. A large number of synthetic and natural antioxidants are known to induce beneficial effects on human health and disease prevention. Cardioprotective ability of grape seed extract polyphenols (GSEP) was studied in animal... | Randomized, Cross-Over, Double Blind, Placebo-Controlled Study of Grape Seed Extract in Treating Patients With Mild Hyperlipidemia | [
{
"description": "Drug {Each Containing: Grape Seed Extract100 mg +...}<br/>1 capsule twice daily for 2 months",
"name": "Grape Seed Extract (Vitagrape)",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Iran Ministry of Health Registration Number: 5/92/43198",
"Vi... | [
{
"design_group_description": "Enrolled patients who are randomly assigned to receive Grape Seed Extract capsules",
"design_group_title": "Grape Seed Extract",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
... | [
"Hyperlipidemia"
] | [
"Shahid Beheshti University of Medical Sciences"
] | [
"University of Tabriz"
] | [
[
{
"name": "่ก่็ฑฝๆๅ็ฉ",
"lang": "CN"
},
{
"name": "Grape Seed Extract",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "GSE"
}
] |
NCT06424834 | [
{
"id_field": "org_study_id",
"id_value": [
"IRB-75085"
]
},
{
"id_domain": "American Heart Association",
"id_field": "secondary_id",
"id_type": "Other Grant/Funding Number",
"id_value": [
"24POST1189688"
]
},
{
"id_field": "acronym",
"id_value": [
"... | https://clinicaltrials.gov/study/NCT06424834 | Efficacy of Targeted Medical Therapy in Angina and Nonobstructive Coronary Arteries | The goal of this clinical trial is to learn if targeted medical therapy will improve symptoms and quality of life in patients with angina and non-obstructive coronary arteries compared to placebo, after the underlying cause of the chest pain has been ascertained by coronary function testing.<br/>Participants will be tr... | A Randomized Controlled Study of Targeted Medical Therapy Versus Placebo for Angina and Non- Obstructive Coronary Arteries: The MVP-ANOCA Study | [
{
"description": "Amlodipine taken once orally daily at a starting dose of 2.5mg, uptitrated to a maximum of 10mg if tolerated.",
"name": "Amlodipine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Katerzia",
"Norliqva",
"Norvasc"
],
"type": "Drug"... | [
{
"design_group_description": "1. Epicardial or microvascular coronary spasm: Amlodipine 2.5mg initial dose, 10mg max dose<br/>2. Coronary microvascular dysfunction: Nebivolol 5mg initial dose, 20mg max dose<br/>3. Myocardial Bridge: Nebivolol 5mg initial dose, 20mg max dose<br/>4. Mixed epicardial/microvascula... | [
"Angina Pectoris",
"Microvascular Angina",
"Vasospastic Angina",
"Myocardial Bridge of Coronary Artery"
] | [
"Stanford University"
] | [
"American Heart Association, Inc."
] | [
[
{
"name": "็้
ธๅฅๅฟ
ๆดๅฐ",
"lang": "CN"
},
{
"name": "Nebivolol hydrochloride",
"lang": "EN"
}
],
[
{
"name": "่ฏ็ฃบ้
ธๆฐจๆฐฏๅฐๅนณ",
"lang": "CN"
},
{
"name": "Amlodipine Besylate",
"lang": "EN"
},
{
"name": "ใขใ ใญใธใใณใใทใซ้
ธๅกฉ",
"lang": "J... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "MVP-ANOCA"
}
] |
NCT01306331 | [
{
"id_field": "org_study_id",
"id_value": [
"AMP001"
]
}
] | https://clinicaltrials.gov/study/NCT01306331 | Study of Contraceptive Efficacy & Safety of Phexxiโข (Previously Known as Amphora) Gel Compared to Conceptrol Vaginal Gel | This is a research study of a new experimental vaginal gel that helps in vaginal pH regulation and results in immobilization of spermatozoa by maintaining the normally low vaginal pH, even in the presence of semen. This vaginal gel is called Phexxiโข (previously known as Amphora) and was compared to a commercially avail... | A Multicenter, Open-Label, Randomized Study of the Contraceptive Efficacy and Safety of Phexxiโข (Previously Known as Amphora) Gel Compared to Conceptrol Vaginal Gel | [
{
"description": "โข Conceptrolยฎ Vaginal Gel, which contains 100 mg (4% concentration) of nonoxynol-9 (N-9) in 2.5 mL volume of gel.",
"name": "Conceptrol",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "โข Amphoraโข gel, which will be delivered in 5 ... | [
{
"design_group_description": "100 mg (4% concentration) of nonoxynol-9 in 2.5 mL volume of gel",
"design_group_title": "Conceptrol",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_d... | [
"Contraception"
] | [
"Evofem, Inc."
] | [
"Health Decisions, Inc."
] | [
[
{
"name": "Amphora",
"lang": "EN"
}
]
] | null |
NCT04650087 | [
{
"id_field": "org_study_id",
"id_value": [
"Pro00107078"
]
}
] | https://clinicaltrials.gov/study/NCT04650087 | COVID-19 Thrombosis Prevention Trials: Post-hospital Thromboprophylaxis | A multicenter, adaptive, randomized platform trial evaluating the efficacy and safety of antithrombotic strategies in patients with COVID-19 following hospital discharge | COVID-19 Post-hospital Thrombosis Prevention Trial: An Adaptive, Multicenter, Prospective, Randomized Platform Trial Evaluating the Efficacy and Safety of Antithrombotic Strategies in Patients With COVID-19 Following Hospital Discharge | [
{
"description": "Participants will take Apixaban 2.5 MG twice a day, once in the morning and once in the evening for 30 days. Participants will be contacted (electronic or telephone) 2 days after starting the study medication and will continue up to day 90 after starting study treatment. Followup will occur fr... | [
{
"design_group_description": "Drug: Apixaban 2.5 MG Participants will be given study medication at the time of discharge from the hospital. Participants will take Apixaban 2.5 MG twice a day, once in the morning and once in the evening, for 30 days. Participants will be contacted (electronic or telephone) 2 da... | [
"Covid19"
] | [
"Duke University"
] | [
"National Heart, Lung & Blood Institute"
] | [
[
{
"name": "้ฟๅๆฒ็ญ",
"lang": "CN"
},
{
"name": "Apixaban",
"lang": "EN"
},
{
"name": "ใขใใญใตใใณ",
"lang": "JP"
}
]
] | null |
NCT00859898 | [
{
"id_field": "org_study_id",
"id_value": [
"MB102-034"
]
},
{
"id_field": "secondary_id",
"id_value": [
"Eudract #: 2008-007548-33"
]
}
] | https://clinicaltrials.gov/study/NCT00859898 | Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes | The primary purpose of this study is to compare the change from baseline in hemoglobin A1C achieved with dapagliflozin 10 mg in combination with metformin XR as compared with metformin XR monotherapy and compared with Dapagliflozin monotherapy, after 24 weeks of oral administration of double-blind treatment. The safety... | A Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin 10 mg in Combination With Metformin as Initial Therapy as Compared With Dapagliflozin 10 mg Monotherapy and Metformin Monotherapy in Subjects With Type 2 Diabetes Who Have Inade... | [
{
"description": "Tablets, Oral, 10 mg, once daily, 24 weeks",
"name": "Dapagliflozin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Farxigaโข"
],
"type": "Drug"
},
{
"description": "Tablets, Oral, up to 2000 mg, once daily, 24 weeks",
"name": "Met... | [
{
"design_group_description": "Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks<br/>Metformin XR: Tablets, Oral, up to 2000 mg, once daily, 24 weeks",
"design_group_title": "Dapagliflozin + Metformin XR",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b3... | [
"Type 2 Diabetes Mellitus"
] | [
"AstraZeneca PLC"
] | [
"Bristol Myers Squibb Co."
] | [
[
{
"name": "่พพๆ ผๅๅ",
"lang": "CN"
},
{
"name": "Dapagliflozin",
"lang": "EN"
},
{
"name": "ใใใฐใชใใญใธใณใใญใใฌใณใฐใชใณใผใซๆฐดๅ็ฉ",
"lang": "JP"
}
],
[
{
"name": "ไบ็ฒๅ่",
"lang": "CN"
},
{
"name": "Metformin",
"lang": "EN"
}
]
] | null |
NCT06819878 | [
{
"id_field": "org_study_id",
"id_value": [
"GA45331"
]
},
{
"id_field": "secondary_id",
"id_type": "EU Trial (CTIS) Number",
"id_value": [
"2024-513053-69-00"
]
},
{
"id_field": "acronym",
"id_value": [
"SIBERITE-1"
]
}
] | https://clinicaltrials.gov/study/NCT06819878 | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease | This Phase III, multicenter, double-blind, placebo-controlled treat-through study will evaluate the efficacy and safety of induction and maintenance therapy with Afimkibart (also known as RO7790121) in participants with moderately to severely active Crohn's disease (CD). | A Phase III, Multicenter, Double-Blind, Placebo-Controlled, Treat-Through Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With RO7790121 in Patients With Moderately to Severely Active Crohn's Disease | [
{
"description": "Afimkibart will be administered as IV infusion. Afimkibart will be administered as SC injection.",
"name": "Afimkibart",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"PF-06480605",
"RG6631",
"RO7790121",
"RVT-3101"
],
"type"... | [
{
"design_group_description": "Participants will receive afimkibart intravenously (IV) followed by afimkibart subcutaneous (SC) injection.",
"design_group_title": "Arm 1: Afimkibart",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"int... | [
"Moderately to Severely Active Crohns Disease"
] | [
"Hoffmann-La Roche Ltd."
] | [
"Chugai Pharmaceutical Co., Ltd."
] | [
[
{
"name": "Afimkibart",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "SIBERITE-1"
}
] |
NCT05985798 | [
{
"id_field": "org_study_id",
"id_value": [
"MIIR-13"
]
}
] | https://clinicaltrials.gov/study/NCT05985798 | Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC | This study is conducted to evaluate the efficacy and safety of sintilimab, bevacizumab plus TACE (Sin-Bev-TACE) compared with lenvatinib plus TACE (Len-TACE) for patients with advanced stage hepatocellular carcinoma (HCC). | Sintilimab, Bevacizumab Plus TACE Versus Lenvatinib Plus TACE for Advanced Stage Hepatocellular Carcinoma: A Randomized Controlled Trial | [
{
"description": "Sintilimab (200mg I.V. q3w) and bevacizumab (7.5mg/kg I.V. q3w) are administered at 3-7 days after the first TACE. The study treatment of sintilimab and bevacizumab will last up to 24 months. TACE can be repeated on demand.",
"name": "Sin-Bev-TACE",
"normalized_type": "3d1aa88261d64c03... | [
{
"design_group_description": "Sintilimab, bevacizumab plus TACE",
"design_group_title": "Sin-Bev-TACE",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Sintilimab (200mg I.... | [
"Hepatocellular Carcinoma Non-resectable"
] | [
"Second Affiliated Hospital of Guangzhou Medical University"
] | [
"Affiliated Tumor Hospital of Guangzhou Medical University",
"Zhongshan People's Hospital"
] | [
[
{
"name": "ไฟก่ฟชๅฉๅๆ",
"lang": "CN"
},
{
"name": "Sintilimab",
"lang": "EN"
}
],
[
{
"name": "่ดไผ็ ๅๆ",
"lang": "CN"
},
{
"name": "Bevacizumab",
"lang": "EN"
},
{
"name": "ใใใทใบใใ๏ผ้บไผๅญ็ตๆใ๏ผ",
"lang": "JP"
}
]
] | null |
NCT00021281 | [
{
"id_field": "org_study_id",
"id_value": [
"CDR0000068766"
]
},
{
"id_field": "secondary_id",
"id_value": [
"UCLA-001003701"
]
},
{
"id_field": "secondary_id",
"id_value": [
"SUGEN-SU5416.035"
]
},
{
"id_field": "secondary_id",
"id_value": [... | https://clinicaltrials.gov/study/NCT00021281 | Combination Chemotherapy With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. SU5416 may stop the growth of tumor cells by stopping blood flow to the tumor. It is not yet known whether combination chemotherapy will be more effective with or without SU5416 in treating metastatic... | A Phase III, Randomized, Open-Label Multicenter, International Study Comparing The Combination Of SU5416/Irinotecan/5-Fluorouracil/Leucovorin Versus Irinotecan/Fluorouracil/Leucovorin Alone As First-Line Therapy Of Patient With Previously Untreated Metastatic Colorectal Cancer | [
{
"name": "FOLFIRI regimen",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"name": "fluorouracil",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
},
{
"name": "irinotecan hydrochloride",
... | null | [
"Colorectal Cancer"
] | [
"Jonsson Comprehensive Cancer Center"
] | [
"National Cancer Institute"
] | [
[
{
"name": "ๅธ้ฉฌๆฒๅฐผ",
"lang": "CN"
},
{
"name": "Semaxanib",
"lang": "EN"
}
],
[
{
"name": "ไบๅถ้
ธ้",
"lang": "CN"
},
{
"name": "Leucovorin Calcium",
"lang": "EN"
},
{
"name": "ใใชใใผใใซใซใทใฆใ ",
"lang": "JP"
}
],
[
... | null |
NCT04861259 | [
{
"id_field": "org_study_id",
"id_value": [
"BO42353"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2020-002475-35"
]
},
{
"id_field": "secondary_id",
"id_type": "EU Trial (CTIS) Number",
"id_value": [
"2023-505089-27... | https://clinicaltrials.gov/study/NCT04861259 | A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS) | This study aims to evaluate the efficacy and safety of crovalimab in adult and adolescent participants with aHUS. | A Phase III, Multicenter, Single-Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Adult and Adolescent Patients With Atypical Hemolytic Uremic Syndrome (aHUS) | [
{
"description": "Crovalimab will be administered at a dose of 1000 milligrams (mg) intravenous (IV) (for participants with body weight at least 40 (>=) and up to 100 kilograms (kg) or 1500 mg IV (for participants with body weight >=100kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, it will be adm... | [
{
"design_group_description": "Participants will be enrolled in three cohorts: [1] Naive Cohort - participants who have not been previously treated with complement inhibitor therapy; [2] Switch Cohort - participants who switch to crovalimab from another Complement Component 5 (C5) inhibitor and [3] C5 Single Nu... | [
"Atypical Hemolytic Uremic Syndrome"
] | [
"Hoffmann-La Roche, Inc."
] | [
"Chugai Pharmaceutical Co., Ltd."
] | [
[
{
"name": "ๅฏไผๅฉๅๆ",
"lang": "CN"
},
{
"name": "Crovalimab",
"lang": "EN"
},
{
"name": "ใฏใญใใชใใ๏ผ้บไผๅญ็ตๆใ๏ผ๏ผJAN๏ผ",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "COMMUTE-a"
},
{
"identifier_source": [
{
"code": "a8528ea52a80244a2a50deae8532a892",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
... |
NCT01124929 | [
{
"id_field": "org_study_id",
"id_value": [
"Abdominal TB_RCT (RNTCP-DOTS)"
]
},
{
"id_field": "acronym",
"id_value": [
"RNTCP-DOTS"
]
}
] | https://clinicaltrials.gov/study/NCT01124929 | Treatment Duration for Abdominal Tuberculosis | Most of the guidelines on the treatment of tuberculosis suggest that 6 months treatment is sufficient for extrapulmonary tuberculosis except for bone tuberculosis and tubercular meningitis. Despite these recommendations, most physicians treating abdominal tuberculosis use antituberculous therapy for 9 months, sometimes... | A Multi-centric Study on Treatment of Abdominal Tuberculosis (Intestinal or Peritoneal): A Randomized Controlled Trial to Compare the 6 Months of Cat I Treatment With 9 Months of Cat I Treatment (Extension for 3 Months) in Abdominal Tuberculosis Under the Revised National Tuberculosis Control Program | [
{
"description": "2H3R3Z3 E3 + 4H3R3",
"name": "RNTCP Category I treatment for 6 months",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "2H3R3Z3 E3 + 7H3R3",
"name": "RNTCP Category I treatment for 9months",
"normalized_type": "3d1aa88261d6... | [
{
"design_group_description": "Anti-tuberculosis drugs",
"design_group_title": "Arm 1: Category I treatment for 6 months",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description"... | [
"Tuberculosis"
] | [
"All India Institute of Medical Sciences"
] | [
"Sanjay Gandhi Post Graduate Institute of Medical Sciences",
"Christian Medical College & Hospital"
] | [
[
{
"name": "ไน่บๅกๅชๅฉ็ฆๅผ็",
"lang": "CN"
},
{
"name": "Ethambutol Hydrochloride/Isoniazid/Pyrazinamide/Rifampicin",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "RNTCP-DOTS"
}
] |
NCT05736861 | [
{
"id_field": "org_study_id",
"id_value": [
"Pro00107921_A"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"3U24TR001608-05W1"
]
}
] | https://clinicaltrials.gov/study/NCT05736861 | ACTIV-6: COVID-19 Study of Repurposed Medications - Arm A (Ivermectin 400) | The purpose of this study is to evaluate the effectiveness of repurposed medications (study drug(s) in reducing symptoms of non-hospitalized participants with mild to moderate COVID-19. Participants will receive either study drug or placebo. They will self-report any new or worsening symptoms or medical events they may... | ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications | [
{
"description": "Each participant will receive a sufficient quantity of 7-mg tablets to be taken as directed based on their weight. The tablets are white, round, biconvex tablets with \"123\" over the scoring on one side. All packaging will be labeled to indicate that the product is for investigational use.",
... | [
{
"design_group_description": "Ivermectin - 7-mg tablets<br/>Participant will be instructed to take a pre-specified number of tablets for 3 consecutive days based on their weight for a daily dose of approximately 300-400 ยตg/kg.",
"design_group_title": "Arm A - Ivermectin 400",
"design_group_type": "Expe... | [
"Covid19"
] | [
"Duke University"
] | [
"Vanderbilt University Medical Center",
"National Center for Advancing Translational Sciences"
] | [
[
{
"name": "ไผ็ปด่็ด ",
"lang": "CN"
},
{
"name": "Ivermectin",
"lang": "EN"
},
{
"name": "ใคใใซใกใฏใใณ",
"lang": "JP"
}
]
] | null |
NCT02419664 | [
{
"id_field": "org_study_id",
"id_value": [
"Ga-PET version 8 (141017)"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2010-020482-24"
]
}
] | https://clinicaltrials.gov/study/NCT02419664 | Ga-68-DOTATOC -PET in the Management of Pituitary Tumours | Title: Gallium (GA) -68-DOTATOC -PET (positron emission tomography) in the management of pituitary tumours Medical product: Ga-68-DOTATOC in PET/computer tomography (CT) Route of administration: Intravenously Diseases of interest: Pituitary tumours Aim: To study the detection of pituitary tumours with Ga-68-DOTATOC -PE... | Ga-68-DOTATOC -PET in the Management of Pituitary Tumours | [
{
"description": "The intervention is to administer Ga-68 DOTATOC in pituitary patients doing PET/CT",
"name": "Gallium-68 DOTATOC PET",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Ga-PET"
],
"type": "Drug"
}
] | [
{
"design_group_description": "To give Ga-68 DOTATOC in pituitary patients doing PET/CT<br/>They are compared with Ga-68 DOTATOC PET performed in another study on patients with no pituitary disease.",
"design_group_title": "Ga-68 DOTATOC PET in pituitary adenomas",
"design_group_type": "Experimental",
... | [
"Pituitary Tumours"
] | [
"University of Gothenburg"
] | [
"Sahlgrenska Universitetssjukhuset",
"University of Uppsala"
] | [
[
{
"name": "้[68Ga]ไผ็ดขๆฒ่ฝ",
"lang": "CN"
},
{
"name": "68Ga-Edotreotide",
"lang": "EN"
}
]
] | null |
NCT02385097 | [
{
"id_field": "org_study_id",
"id_value": [
"CHL.2/01-2014/M"
]
}
] | https://clinicaltrials.gov/study/NCT02385097 | Chloroprocaine 2% vs Ropivacaine 0.75% in Ultrasound-guided Axillary Nerve Block | The Study evaluate the non-inferiority of Test product (Chloroprocaine 2%) versus Reference product (Ropivacaine 0.75%) in terms of proportion of subjects with a successful block for distal upper limb surgeries Successful block: anaesthesia adequate for the surgery without any supplementation in the first 45 min. | A Prospective, Randomised, Non-inferiority Study of Chloroprocaine 2% and the Active Control Ropivacaine 0.75% (AstraZeneca) in Ultrasound-guided Axillary Nerve Block for Short-duration Distal Upper Limb Surgery | [
{
"description": "Single Administration (20mL) by Axillary Nerve Route",
"name": "Chloroprocaine HCl 2%",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Ampres"
],
"type": "Drug"
},
{
"description": "Single Administration (20mL) by Axillary Nerve Route"... | [
{
"design_group_description": "Chloroprocaine 2 % Solution for injection, single administration by axillary nerve route 20 mL",
"design_group_title": "Chloroprocaine HCl 2% (20 mg/mL)",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"i... | [
"Axillary Nerve Block"
] | [
"Sintetica SA"
] | [
"Cross SA"
] | [
[
{
"name": "็้
ธๆฐฏๆฎ้ฒๅกๅ ",
"lang": "CN"
},
{
"name": "Chloroprocaine Hydrochloride",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"code": "4e8330433a422534a505a252a8aa4388",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "52580e52d9290852d90aa2532285a43e",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "not... |
NCT00441584 | [
{
"id_field": "org_study_id",
"id_value": [
"P03833"
]
},
{
"id_field": "secondary_id",
"id_value": [
"ESPECIAL"
]
}
] | https://clinicaltrials.gov/study/NCT00441584 | The Effects of PegIntron Plus Rebetol in Subjects With Chronic Hepatitis C Not Responding to Pegasys (Study P03833) | This is an uncontrolled, non-randomized, open-label, multinational study designed to evaluate the efficacy and safety of PegIntron plus Rebetol in subjects with chronic hepatitis C. The study is designed to determine the proportion of chronic hepatitis C genotype 1 subjects who did not respond to previous treatment wit... | Efficacy and Safety of PEG-Intron Plus Rebetol in Subjects With Chronic Hepatitis C Genotype 1 Non Responder to Pegasys | [
{
"description": "Powder for injection in vial or Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks",
"name": "PegIntron (peginterferon alfa-2b)",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"S... | [
{
"design_group_description": "PegIntron 1.5 ฮผg/kg/week plus Rebetol 800-1400 mg/day administered for 48 weeks",
"design_group_title": "PegIntron plus Rebetol",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
... | [
"Hepatitis C, Chronic"
] | [
"Merck Sharp & Dohme Corp."
] | [
"Integrated Therapeutics Group, Inc."
] | [
[
{
"name": "่ไนไบ้ๅนฒๆฐ็ด ฮฑ-2bๆณจๅฐ(Merck & Co)",
"lang": "CN"
},
{
"name": "Peginterferon alfa-2b(Merck & Co)",
"lang": "EN"
}
],
[
{
"name": "ๅฉๅทด้ฆๆ",
"lang": "CN"
},
{
"name": "Ribavirin",
"lang": "EN"
},
{
"name": "ใชใใใชใณ",
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "2d32a29d80982a85deaa892d398549e5",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "P03833"
}
] |
NCT06258811 | [
{
"id_field": "org_study_id",
"id_value": [
"TopHill"
]
}
] | https://clinicaltrials.gov/study/NCT06258811 | Neoadjuvant Immunochemotherapy for LAOSCC | To evaluate the prognostic efficacy of neoadjuvant immunochemotherapy with tislelizumab, albumin paclitaxel and cisplatin followed by radical surgery and adjuvant therapy compared with standard therapy for patients with locally advanced and resectable oral squamous cell carcinoma. | Neoadjuvant Immunochemotherapy With Tislelizumab, Albumin Paclitaxel and Cisplatin Followed by Standard Therapy Versus Standard Therapy for Locally Advanced Oral Squamous Cell Carcinoma, a Multicenter Randomized Phase 3 Trial | [
{
"description": "Neoadjuvant immunochemotherapy (2 cycles, and 21 days each cycle, 260mg/m2 albumin paclitaxel intravenously on day 1 and day 22, with 75mg/m2 of cisplatin and 200mg of tislelizumab) + radical surgery + adjuvant therapy (radiation/chemoradiation followed by 200mg of tislelizumab, every 3 weeks ... | [
{
"design_group_description": "Neoadjuvant immunochemotherapy (albumin paclitaxel+cisplatin+tislelizumab) + radical surgery + adjuvant therapy (radiation/chemoradiation + tislelizumab maitainance)",
"design_group_title": "Experimental arm",
"design_group_type": "Experimental",
"design_group_type_nor... | [
"Oral Squamous Cell Carcinoma",
"Locally Advanced Head and Neck Carcinoma"
] | [
"Shanghai Huashan Hospital"
] | [
"Fujian Medical University",
"Central South University",
"Sun Yat-Sen University",
"Fudan University"
] | [
[
{
"name": "ๆฟ้ทๅฉ็ ๅๆ",
"lang": "CN"
},
{
"name": "Tislelizumab",
"lang": "EN"
},
{
"name": "ใในใฌใชใบใใ๏ผ้บไผๅญ็ตๆใ๏ผ๏ผJAN๏ผ",
"lang": "JP"
}
]
] | null |
NCT04192266 | [
{
"id_field": "org_study_id",
"id_value": [
"HSC-MS-23-0497"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R33MH111907"
]
},
{
"id_field": "nct_alias",
"id_value": [
"NCT03371654"
]
},
{
"id_field": "... | https://clinicaltrials.gov/study/NCT04192266 | Estrogen and Fear in PTSD | The purpose of this research study is to determine if taking a pill of estradiol (E2) together with prolonged exposure (PE) therapy can improve this treatment outcome in women diagnosed with Post-Traumatic Stress Disorder (PTSD). 80 subjects will take part in this research study across UTHealth Houston and UPenn (40 su... | A Randomized, Double-blind Placebo-controlled Multi-center Study of Identifying Neural Mechanisms of PTSD Symptom Reduction Induced by Combined Estrogen and Prolonged Exposure Therapy | [
{
"description": "2.0 mg of estradiol will be taken by mouth by the study participant 5-6 hours before each of 5 PE treatment sessions (Session 2- 6)",
"name": "Estradiol",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Estrace"
],
"type": "Drug"
},
{
"... | [
{
"design_group_description": "A single 2mg dose of estradiol (a form of estrogen) will be taken at home by the study participant 5-6 hours before each of 5 prolonged exposure (PE) therapy treatment sessions (sessions 2 to 6). PE therapy is a validated treatment for PTSD.",
"design_group_title": "Prolonged ... | [
"PTSD"
] | [
"The University of Texas Health Science Center at Houston"
] | [
"National Institute of Mental Health"
] | [
[
{
"name": "ๆ้
ธ้ไบ้",
"lang": "CN"
},
{
"name": "Estradiol Valerate",
"lang": "EN"
},
{
"name": "ใจในใใฉใธใชใผใซๅ่้
ธใจในใใซ",
"lang": "JP"
}
]
] | null |
NCT02060903 | [
{
"id_field": "org_study_id",
"id_value": [
"Ha03-001"
]
}
] | https://clinicaltrials.gov/study/NCT02060903 | A Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice Infestation | The purpose of the study was to assess the efficacy, safety and tolerability of a single application of abametapir lotion 0.74% w/w compared to a vehicle control, when applied to the scalp and hair for 10 minutes at home. | A Randomized, Double-Blind, Multicenter, Vehicle-Controlled Study of the Efficacy and Safety of Abametapir Lotion 0.74% Administered for the Treatment of Head Lice Infestation | [
{
"description": "Abametapir Lotion 0.74% was dispensed to subjects on Day 0 for self-administration at home on the same day.",
"name": "Abametapir Lotion 0.74% w/w",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Abametapir 0.74%"
],
"type": "Drug"
},
{
... | [
{
"design_group_description": "Single topical treatment administered to hair and scalp for 10 minutes. Applied at home by a subject/caregiver.",
"design_group_title": "Abametapir Lotion 0.74% w/w",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e... | [
"Head Lice Infestation"
] | [
"Dr. Reddy's Laboratories Ltd. (Russia)"
] | [
"Accelovance, Inc.",
"Syneos Health, Inc."
] | [
[
{
"name": "Abametapir",
"lang": "EN"
}
]
] | null |
NCT01324934 | [
{
"id_field": "org_study_id",
"id_value": [
"AP-AS-24-ES"
]
},
{
"id_field": "acronym",
"id_value": [
"IBERICA"
]
}
] | https://clinicaltrials.gov/study/NCT01324934 | Efficacy and Safety of ATG-Fresenius Following a Renal Transplantation, Without Corticosteroids | The main objective of the study is the assessment of the overall graft rejection rate (acute, chronic and subclinical) between a treatment with ATG-Fresenius administered in addition to standard treatment consisting of CellCeptยฎ or Myforticยฎ/TAC and without corticosteroids and a treatment consisting of CellCeptยฎ or Myf... | Prospective, Randomized, Multi-center, Open Label, Phase III Study to Evaluate the Efficacy and Safety of Immunosuppression Following a Heart-beating Cadaveric Renal Transplantation Based on the Use of Rabbit Anti-T-lymphocyte Serum, Tacrolimus and Mycophenolate, Free of Concomitant Corticosteroids From the Start of Im... | [
{
"description": "Dosage: Single high-dose of 9 mg/kg pre-operatively, followed by 3 mg/kg/d at day +2 and +4. ATG-Fresenius treatment at Days 0, +2, and +4 is mandatory.<br/>(In case of persisting DGF, the treatment is left to the discretion of the investigator. Treatment options include the continuation of AT... | [
{
"design_group_description": "immunosuppressive treatment consisting of ATG-Fresenius/TAC/MMF or Myfortic",
"design_group_title": "Study Group",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"in... | [
"Renal Transplant Rejection"
] | [
"Neovii Biotech GmbH"
] | [
"Eurotrials Brasil Consultores Cientรญficos Ltda.",
"PsyConsult VOF"
] | [
[
{
"name": "ๆไบบT็ป่ๅ
ๅ
็ซ็่็ฝ",
"lang": "CN"
},
{
"name": "Anti-human T Lymphocyte Rabbit Immunoglobulin",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "IBERICA"
}
] |
NCT03840421 | [
{
"id_field": "org_study_id",
"id_value": [
"2018-FXY-140"
]
}
] | https://clinicaltrials.gov/study/NCT03840421 | GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma | The purpose of this study is to compare the survival and toxicity of GP (gemcitabine and cisplatin) vs. PF (cisplatin and fluorouracil) as induction chemotherapy combined with concurrent chemoradiotherapy (CCRT) for locoregionally advanced nasopharyngeal carcinoma( NPC ) patients. | GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma๏ผa Prospective,Parallel, Randomized, Open Labeled, Multicenter Phase III Clinical Trial | [
{
"description": "Patients receive gemcitabine (1000 mg/mยฒ d1,8) and cisplatin (80mg/mยฒ d1) every 3 weeks for 3 cycles before concurrent chemoradiotherapy.",
"name": "gemcitabine and cisplatin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"gemcitabine and cisplatin (... | [
{
"design_group_description": "Patients receive gemcitabine (1000 mg/mยฒ d1,8) and cisplatin (80mg/mยฒ d1) every 3 weeks for 3 cycles before radiotherapy, and then receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 100 mg/mยฒ every 3 weeks for 2 cycles.",
"design_group_title": "gemcit... | [
"Nasopharyngeal Carcinoma",
"Nasopharyngeal Neoplasms",
"Nasopharyngeal Diseases",
"Head and Neck Neoplasm"
] | [
"Sun Yat-Sen University"
] | [
"Guangdong General Hospital",
"the First Affiliated Hospital of Sun Yat-Sen University"
] | [
[
{
"name": "ๅ่ฅฟไปๆปจ",
"lang": "CN"
},
{
"name": "Gemcitabine",
"lang": "EN"
}
],
[
{
"name": "้กบ้",
"lang": "CN"
},
{
"name": "Cisplatin",
"lang": "EN"
},
{
"name": "ใทในใใฉใใณ",
"lang": "JP"
}
]
] | null |
NCT03155997 | [
{
"id_field": "org_study_id",
"id_value": [
"16338"
]
},
{
"id_domain": "Eli Lilly and Company",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"I3Y-MC-JPCF"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_... | https://clinicaltrials.gov/study/NCT03155997 | Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer | The purpose of this study is to evaluate the safety and efficacy of the study drug abemaciclib in participants with high risk, node positive, early stage, hormone receptor positive (HR+), human epidermal receptor 2 negative (HER2-), breast cancer. | A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer | [
{
"description": "Administered orally.",
"name": "Abemaciclib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"LY2835219"
],
"type": "Drug"
},
{
"description": "Administered according to label instructions.",
"name": "Standard Adjuvant Endocrine The... | [
{
"design_group_description": "Participants received Abemaciclib orally at 150 milligrams (mg) twice daily with at least 6 hours between doses for up to 2 years or until evidence of disease recurrence or other discontinuation criteria were met, whichever occurs first. Endocrine therapy (physicians' choice) stan... | [
"Breast Cancer"
] | [
"Eli Lilly & Co."
] | [
"NSABP Foundation, Inc."
] | [
[
{
"name": "้ฟ่ด่ฅฟๅฉ",
"lang": "CN"
},
{
"name": "Abemaciclib",
"lang": "EN"
},
{
"name": "ใขใใใทใฏใชใ",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "0e2ae0325842a03ed85238058d220242",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "20a02229aa022e52ee282a5392a88845",
"s... |
NCT02593773 | [
{
"id_field": "org_study_id",
"id_value": [
"HZNP-ACT-302"
]
},
{
"id_field": "acronym",
"id_value": [
"STEADFAST"
]
}
] | https://clinicaltrials.gov/study/NCT02593773 | Safety, Tolerability and Efficacy of ACTIMMUNEยฎ Dose Escalation in Friedreich's Ataxia Study | The purpose of this phase 3 multi-center, open-label extension study is to evaluate the long-term safety of ACTIMMUNEยฎ (interferon-ฮณ 1b) in participants with Friedreich's Ataxia. | Multicenter, Safety and Efficacy, Open-Label Extension Study of ACTIMMUNEยฎ (Interferon ฮณ-1b) in Children and Young Adults With Friedreich's Ataxia | [
{
"description": "The study drug dose is planned to be escalated on a weekly basis over the first 4 weeks of treatment (from 10 ยตg/mยฒ to 25, 50, and 100 ยตg/mยฒ). The dose may be reduced, interrupted, or held based on tolerability. By Week 13, all participants are to be on a stable tolerated dose of study drug in... | [
{
"design_group_description": "Subcutaneous (SC) doses of ACTIMMUNEยฎ TIW for a total of 26 weeks.",
"design_group_title": "interferon ฮณ-1b",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention... | [
"Friedreich's Ataxia"
] | [
"Amgen, Inc."
] | [
"The Friedreich's Ataxia Research Alliance"
] | [
[
{
"name": "ๅนฒๆฐ็ด ฮณ-1b",
"lang": "CN"
},
{
"name": "Interferon gamma-1b",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "8d20a95a4042593e89dde0a22ea5d532",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "STEADFAST"
}
] |
NCT00001127 | [
{
"id_field": "org_study_id",
"id_value": [
"DMID 99-021"
]
},
{
"id_field": "secondary_id",
"id_value": [
"AV012"
]
},
{
"id_field": "secondary_id",
"id_value": [
"AV012;DMID 99-021"
]
}
] | https://clinicaltrials.gov/study/NCT00001127 | Study of a Flu Vaccine in Children | This study tests the safety and effectiveness of a flu vaccine in school children.<br/>School children are usually the first members of a community to come down with the flu, and they often give the flu to their younger siblings, parents, and grandparents. It is hoped that giving school children a flu vaccine can help ... | Study of the Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) in a Community-Based, Non-Randomized, Open-Label Trial in Children to Assess Safety and Herd Immunity for the Control of Epidemic Influenza | [
{
"name": "Influenza virus vaccine (CAIV-T)",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"single_or_multi": "single_drug",
"type": "Biological"
}
] | null | [
"Influenza"
] | [
"National Institute of Allergy & Infectious Diseases"
] | [
"Aviron LLC"
] | [
[
{
"name": "Influenza virus vaccine(Protein Sciences Corp.)",
"lang": "EN"
}
]
] | null |
NCT00336167 | [
{
"id_field": "org_study_id",
"id_value": [
"05-05-19"
]
}
] | https://clinicaltrials.gov/study/NCT00336167 | Bezafibrate Trial in CPT2 Deficiency | The purpose of this study is to determine whether bezafibrate is effective in the treatment of the muscular adult form of carnitine palmitoyltransferase 2 deficiency | Clinical Trial on the Effect of Bezafibrate in the Muscular Form of Carnitine Palmitoyltransferase 2 Deficiency | [
{
"name": "bezafibrate (drug)",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
}
] | null | [
"Carnitine Palmitoyl Transferase 2 Deficiency"
] | [
"Assistance Publique des Hรดpitaux de Paris SA"
] | [
"Institut National de la Santรฉ et de la Recherche Mรฉdicale"
] | [
[
{
"name": "่ฏๆ่ด็น",
"lang": "CN"
},
{
"name": "Bezafibrate",
"lang": "EN"
},
{
"name": "ใใถใใฃใใฉใผใ",
"lang": "JP"
}
]
] | null |
NCT00287079 | [
{
"id_field": "org_study_id",
"id_value": [
"IMP 26222"
]
},
{
"id_field": "acronym",
"id_value": [
"CIS-ON"
]
}
] | https://clinicaltrials.gov/study/NCT00287079 | A Prospective Study Looking at the Use of Rebifยฎ in Subjects With Clinically Isolated Syndrome | The primary objective of this initiative is to assess the effectiveness of subcutaneous (sc) interferon (IFN) beta - 1a, (Rebifยฎ), versus No Treatment in delaying the conversion to Clinically Definite Multiple Sclerosis (CDMS) - as defined by the occurrence of a second exacerbation - over 96 weeks in subjects that pres... | A Prospective, Open Label, Multi-centre Study Exploring the Use of Subcutaneous (sc) 44 Microgram Interferon (IFN) Beta - 1a (Rebifยฎ) Once a Week (qw) in Subjects With Clinically Isolated Syndrome (CIS) | [
{
"description": "44 microgram (mcg) IFN beta-1a sc once a week (qw) for 96 weeks",
"name": "Rebifยฎ",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "No treatment for 96 weeks",
"name": "No Treatment",
"normalized_type": "ffd65a2d86954c7285f... | [
{
"design_group_title": "Rebifยฎ",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "44 microgram (mcg) IFN beta-1a sc once a week (qw) for 96 weeks",
"intervention_name": ... | [
"Clinically Isolated Syndrome"
] | [
"Merck KGaA"
] | [
"EMD Serono Canada Inc."
] | [
[
{
"name": "ๅนฒๆฐ็ด ฮฒ-1a(Merck Serono SA)",
"lang": "CN"
},
{
"name": "INTERFERON BETA-1A(Merck Serono SA)",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "ae852ede4aee4d5ea22ee58a8a8a3a28",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "CIS-ON"
}
] |
NCT00850343 | [
{
"id_field": "org_study_id",
"id_value": [
"CDP870-275-08-004"
]
},
{
"id_field": "secondary_id",
"id_value": [
"JapicCTI-090701"
]
}
] | https://clinicaltrials.gov/study/NCT00850343 | Long-term Treatment Study of Certolizumab Pegol Without Coadministration of Methotrexate in Japanese Rheumatoid Arthritis (RA) Patients | The objectives of this study are to evaluate the safety and efficacy of certolizumab pegol when administered without coadministration of methotrexate over the long term in Japanese RA patients who transferred from Study 275-08-003 (NCT00791921), and to evaluate the effects of different dosing regimens on the safety and... | A Multicenter, Open-label, Long-term Safety Study of CDP870 to Evaluate the Safety and Efficacy of CDP870 Administered Without Coadministration of Methotrexate (MTX) Over the Long Term in Patients With Active Rheumatoid Arthritis Transferred From the Efficacy Confirmatory Study (Study 275-08-003) | [
{
"description": "Subcutaneous (SC) injection",
"name": "Certolizumab pegol",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"CDP870",
"Cimzia"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Participants received 200 mg certolizumab pegol by subcutaneous injection once every 2 weeks for up to 52 weeks or until approval of certolizumab pegol for rheumatoid arthritis in Japan.",
"design_group_title": "Certolizumab pegol 200 mg",
"design_group_type": "Experimenta... | [
"Rheumatoid Arthritis"
] | [
"Astellas Pharma, Inc."
] | [
"UCB Japan Co. Ltd."
] | [
[
{
"name": "ๅนๅกๅฉ็ ๅๆ",
"lang": "CN"
},
{
"name": "Certolizumab Pegol",
"lang": "EN"
},
{
"name": "ใปใซใใชใบใใ ใใดใซ๏ผ้บไผๅญ็ตๆใ๏ผ",
"lang": "JP"
}
]
] | null |
NCT00043537 | [
{
"id_field": "org_study_id",
"id_value": [
"R01MH053703"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01MH053703"
]
}
] | https://clinicaltrials.gov/study/NCT00043537 | Treatment of Childhood Social Phobia | This 4-year study will compare the long-term effectiveness of behavioral treatment, fluoxetine (Prozacยฎ), and placebo for treatment of social phobia in children and adolescents. | Treatment of Childhood Social Phobia | [
{
"name": "Social Effectiveness Therapy for Children (SET-C)",
"normalized_type": "f9cf04e7d3da41f2ae5e11bc777942f7",
"type": "Behavioral"
},
{
"name": "Fluoxetine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"name": "Pill Placebo",
"normalized... | [
{
"design_group_description": "Social Effectiveness Therapy for Children includes social skills training, peer generalization experiences and exposure therapy",
"design_group_title": "Social Effectiveness Therapy for Children",
"design_group_type": "Experimental",
"design_group_type_normalized_id": ... | [
"Social Phobia"
] | [
"University of Central Florida"
] | [
"National Institute of Mental Health"
] | [
[
{
"name": "็้
ธๆฐ่ฅฟๆฑ",
"lang": "CN"
},
{
"name": "Fluoxetine Hydrochloride",
"lang": "EN"
}
]
] | null |
NCT01625182 | [
{
"id_field": "org_study_id",
"id_value": [
"CFTY720I2201"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2011-005280-24"
]
}
] | https://clinicaltrials.gov/study/NCT01625182 | Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. | The study was designed to evaluate the efficacy and safety of fingolimod in the treatment of chronic inflammatory demyelinating polyradiculoneuropathy compared with placebo. | A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Fingolimod 0.5 mg Administered Orally Once Daily Versus Placebo in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | [
{
"description": "Fingolimod 0.5 mg capsules",
"name": "Fingolimod",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Matching placebo capsules",
"name": "Placebo Comparator",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type":... | [
{
"design_group_description": "Participants received Fingolimod 0.5 mg orally once daily.",
"design_group_title": "Fingolimod (FTY720)",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_des... | [
"Chronic Inflammatory Demyelinating Polyradiculoneuropathy"
] | [
"Novartis Pharmaceuticals Corp."
] | [
"Tanabe Pharma Corp."
] | [
[
{
"name": "็้
ธ่ฌๆ่ซๅพท",
"lang": "CN"
},
{
"name": "Fingolimod Hydrochloride",
"lang": "EN"
},
{
"name": "ใใฃใณใดใชใขใๅกฉ้
ธๅกฉ",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"code": "330908d588aee8a5e94ea0d980e02932",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "885282225202824a94438a955d823eed",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "FOR... |
NCT04303026 | [
{
"id_field": "org_study_id",
"id_value": [
"2018030"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2019-000757-31"
]
}
] | https://clinicaltrials.gov/study/NCT04303026 | The Effect of Zoledronic Acid on Patients With Osteoarthritis of the Hip | Hip Osteoarthritis (OA) is one of the most common diseases affecting the ageing population. No specific and safe treatment slowing the development of hip OA as reflected in reduced joint space narrowing has been developed so far. Implantation of hip prosthesis has been a great success, but is expensive and puts a great... | A Randomized Placebo Controlled Trial Testing The Effect of Zoledronic Acid on Hip Osteoarthritis | [
{
"description": "5mg IV infusion",
"name": "Zoledronic Acid",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Active Treatment"
],
"type": "Drug"
},
{
"description": "Placebo Group. Saline 0.9% 100 ml infusion",
"name": "Saline 0.9%",
"normalize... | [
{
"design_group_description": "Participants receiving active treatment with two infusions of Zoledronic Acid 5 mg with 3 months interval mixed in 100 ml 0.9% saline",
"design_group_title": "Treatment Group",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a... | [
"Osteoarthritis, Hip"
] | [
"Martina Hansens Hospital AS"
] | [
"University of Oslo"
] | [
[
{
"name": "ๅๆฅ่ฆ้
ธ",
"lang": "CN"
},
{
"name": "Zoledronic Acid",
"lang": "EN"
},
{
"name": "ใพใฌใใญใณ้
ธๆฐดๅ็ฉ",
"lang": "JP"
}
]
] | null |
NCT02028923 | [
{
"id_field": "org_study_id",
"id_value": [
"IC 2013-01"
]
},
{
"id_field": "acronym",
"id_value": [
"EMGEL"
]
}
] | https://clinicaltrials.gov/study/NCT02028923 | Efficacy of Topical Morphine in the Treatment of Severe Local Pain of Chronic Wounds | This phase III study aims to show that topical morphine low doses treats localized pain in chronic wounds, intense and rebellious to systemic analgesics included or not opioids. | Phase III Study Evaluating the Efficacy of Topical Morphine in the Treatment of Severe Local Pain of Chronic Wounds | [
{
"description": "Topical",
"name": "Morphine gel",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Topical",
"name": "Neutral gel",
"normalized_type": "ffd65a2d86954c7285f258adfa9c2916",
"type": "Other"
}
] | [
{
"design_group_description": "morphine 30 mg, quantity of gel per application: 15mg (15ml)",
"design_group_title": "Morphine gel",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_descript... | [
"Local Pain",
"Chronic Wounds"
] | [
"Institut Curie"
] | [
"Assistance Publique des Hรดpitaux de Paris SA"
] | [
[
{
"name": "็กซ้
ธๅๅก",
"lang": "CN"
},
{
"name": "Morphine Sulfate",
"lang": "EN"
},
{
"name": "ใขใซใใ็กซ้
ธๅกฉๆฐดๅ็ฉ",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "EMGEL"
}
] |
NCT01722240 | [
{
"id_field": "org_study_id",
"id_value": [
"1966"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"1R01DK092653-01A1"
]
},
{
"id_field": "acronym",
"id_value": [
"1966"
]
}
] | https://clinicaltrials.gov/study/NCT01722240 | Liraglutide in Type 1 Diabetes | The glucose lowering effects of GLP-1 agonists are well established in subjects with type 2 diabetes, however, these have not been studied prospectively in subjects with type 1 diabetes. The investigators have, therefore, designed this study to investigate the central hypothesis that in patients with type 1 diabetes, L... | Liraglutide in Type 1 Diabetes | [
{
"name": "Liraglutide 1.8mg",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"name": "Placebo",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Daily Injection",
"design_group_title": "Liraglutide 1.8mg",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_name": "Liraglutide 1.8mg",
"interv... | [
"Type 1 Diabetes"
] | [
"State University of New York at Buffalo"
] | [
"National Institute of Diabetes & Digestive & Kidney Diseases"
] | [
[
{
"name": "ๅฉๆ้ฒ่ฝ",
"lang": "CN"
},
{
"name": "Liraglutide",
"lang": "EN"
},
{
"name": "ใชใฉใฐใซใใ๏ผ้บไผๅญ็ตๆใ๏ผ",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "2ea2925ddeaeaee29a85a2042a54589e",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "1966"
}
] |
NCT00361582 | [
{
"id_field": "org_study_id",
"id_value": [
"CR011218"
]
}
] | https://clinicaltrials.gov/study/NCT00361582 | A Study to Evaluate the Effectiveness and Safety of Multiple Doses of Tapentadol(CG5503) in Patients Awaiting Joint Replacement Surgery | The purpose of this study is to evaluate in patients who are eligible for elective primary total or partial joint replacement of the hip or knee due to chronic osteoarthritis the efficacy (level of pain control) of CG5503 over 5 and 10 days compared with placebo, and to assess the safety and tolerability of multiple do... | A Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Multiple Doses of CG5503 Immediate Release Formulation in Subjects Awaiting Primary Joint Replacement Surgery for End-Stage Joint Disease | [
{
"name": "CG5503 IR; tapentadol",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
}
] | null | [
"Osteoarthritis",
"Pain Assessment",
"Arthralgia"
] | [
"Johnson & Johnson Pharmaceutical Research & Development LLC"
] | [
"Grรผnenthal GmbH"
] | [
[
{
"name": "็้
ธไปๅทไปๅค",
"lang": "CN"
},
{
"name": "Tapentadol Hydrochloride",
"lang": "EN"
},
{
"name": "ใฟใใณใฟใใผใซๅกฉ้
ธๅกฉ",
"lang": "JP"
}
]
] | null |
NCT00408356 | [
{
"id_field": "org_study_id",
"id_value": [
"2004-017"
]
}
] | https://clinicaltrials.gov/study/NCT00408356 | Immunological and Clinical Responses to Zinc in Children With Diarrhoea | Zinc deficiency has been found to be widespread among children in developing countries.Clinical and field studies have consistently observed an association between zinc deficiency and higher rates of infectious diseases, including skin infections, diarrhea, respiratory infections, malaria, and delayed wound healing. Ba... | Immunological and Clinical Responses to Zinc: A Randomized, Double-Blind Trial of Zinc Treatment vs. Zinc Treatment Plus Daily Supplementation for 3 Months Among Children Under 2 Years of Age With an Acute Diarrheal Illness. | [
{
"name": "Zinc",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
}
] | null | [
"Diarrhoea"
] | [
"International Centre for Diarrhoeal Disease Research, Bangladesh"
] | [
"Gates Foundation (United States)"
] | [
[
{
"name": "ๆฐงๅ้",
"lang": "CN"
},
{
"name": "Zinc Oxide",
"lang": "EN"
}
]
] | null |
NCT01143064 | [
{
"id_field": "org_study_id",
"id_value": [
"BHR-100-301"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2010-018283-16"
]
},
{
"id_field": "acronym",
"id_value": [
"SyNAPSe"
]
}
] | https://clinicaltrials.gov/study/NCT01143064 | Efficacy and Safety Study of Intravenous Progesterone in Patients With Severe Traumatic Brain Injury | The SyNAPSe trial will study if giving intravenous (i.v.) progesterone within 8 hours of the injury for a total of 120 hours to severe traumatic brain injury patients improves their recovery. | A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Investigate the Efficacy and Safety of Progesterone in Patients With Severe Traumatic Brain Injury | [
{
"description": "Intravenous administration of 0.71mg/kg/hr for 1hr followed by 0.5mg/kg/hr administered intravenously for an additional 119 hrs.",
"name": "Progesterone",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"BHR-100"
],
"type": "Drug"
},
{
"... | [
{
"design_group_title": "Progesterone",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": "Intravenous administration of 0.71mg/kg/hr for 1hr followed by 0.5mg/kg/hr administe... | [
"Brain Injuries"
] | [
"BHR Pharma LLC"
] | [
"Syneos Health, Inc.",
"PRA Health Sciences, Inc."
] | [
[
{
"name": "้ปไฝ้
ฎ",
"lang": "CN"
},
{
"name": "Progesterone",
"lang": "EN"
},
{
"name": "ใใญใฒในใใญใณ",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "8e4ad4222d25ea25a2dee8d2505a82d2",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "SyNAPSe"
}
] |
NCT00252564 | [
{
"id_field": "org_study_id",
"id_value": [
"05-041"
]
}
] | https://clinicaltrials.gov/study/NCT00252564 | Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer | The purpose of this study is to compare the rates of Progression-Free Survival (PFS) at 12 months for patients treated with Bev-FOLFOX versus patients treated with FOLF-CB for first line treatment of metastatic colorectal cancer. | Randomized PhIII Trial of Cetuximab, Bevacizumab & Biweekly Infusional 5FU/Leucovorin (FOLF-CB) vs. Oxaliplatin, Bevacizumab, & Biweekly Infusional 5FU/Leucovorin (Bev-FOLFOX) in First Line Treatment of Metastatic Colorectal Cancer | [
{
"description": "5 mg/kg over 30 minutes on Days 1 and 15",
"name": "Bevacizumab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Avastin"
],
"type": "Drug"
},
{
"description": "85 mg/m2 on Days 1 and 15",
"name": "Oxaliplatin",
"normalized_typ... | [
{
"design_group_description": "(Bev-FOLFOX): Bevacizumab, followed by oxaliplatin and LV given simultaneously via \"T\" connector over 2 hours, followed by bolus 5-FU followed by infusional 5-FU.<br/>Bevacizumab --> oxaliplatin and LV --> bolus 5-FU --> infusional 5-FU<br/>Dosing on Days 1 and 15 of each 28-day... | [
"Metastatic Colorectal Cancer"
] | [
"US Oncology Research LLC"
] | [
"Memorial Sloan Kettering Cancer Center",
"Bristol Myers Squibb Co.",
"Prologue Research International, Inc."
] | [
[
{
"name": "่ฅฟๅฆฅๆๅๆ",
"lang": "CN"
},
{
"name": "Cetuximab",
"lang": "EN"
},
{
"name": "ใปใใญใทใใ๏ผ้บไผๅญ็ตๆใ๏ผ",
"lang": "JP"
}
],
[
{
"name": "ไบๅถ้
ธ้",
"lang": "CN"
},
{
"name": "Leucovorin Calcium",
"lang": "EN"
},
{
... | null |
NCT07249632 | [
{
"id_field": "org_study_id",
"id_value": [
"RC18-C307"
]
}
] | https://clinicaltrials.gov/study/NCT07249632 | A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG) | This is a Phase III, multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of Telitacicept for the treatment of Ocular Myasthenia Gravis (OMG).Approximately 120 eligible subjects aged 12 to 80 years with a diagnosis of OMG (Myasthenia Gravis Foundation of America [... | A Phase III Trial of Telitacicept in Patients With Ocular Myasthenia Gravis | [
{
"description": "The dosage is administered based on the subject's age and baseline body weight.",
"name": "Telitacicept",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "The placebo contains no active ingredients. To maintain the blind, the placeb... | [
{
"design_group_title": "Telitacicept",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "The dosage is administered based on the subject's age and baseline body weight.",
... | [
"Myasthenia Gravis, Ocular"
] | [
"RemeGen Co., Ltd."
] | [
"Shanghai Huashan Hospital",
"Beijing Hospital of the Ministry of Health"
] | [
[
{
"name": "ๆณฐๅฎ่ฅฟๆฎ",
"lang": "CN"
},
{
"name": "Telitacicept",
"lang": "EN"
}
]
] | null |
NCT04383691 | [
{
"id_field": "org_study_id",
"id_value": [
"D1071301"
]
}
] | https://clinicaltrials.gov/study/NCT04383691 | A Study of Lurasidone Compared With Placebo for the Treatment of Bipolar I Depression | The study evaluates the efficacy and safety of lurasidone compared with placebo in treating Bipolar I Depression. | A Randomized, 6-Week, Multicenter, Double-Blind, Placebo-Controlled, Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression | [
{
"description": "Subjects will be administered orally, once daily, in the evening. Subjects will be treated with Lurasidone 20 mg/day for Days 1-2-3, 40 mg/day for Days 4-5-6, and 60 mg/day on Day 7. Flexible dosing of study drug will be permitted beginning on Day 8.",
"name": "Lurasidone HCl",
"normal... | [
{
"design_group_description": "Subjects will be administered orally, once daily, in the evening. Subjects will be treated with Lurasidone 20 mg/day for Days 1-2-3, 40 mg/day for Days 4-5-6, and 60 mg/day on Day 7. Flexible dosing of study drug will be permitted beginning on Day 8.",
"design_group_title": "L... | [
"Bipolar I Depression"
] | [
"Sumitomo Pharma Co., Ltd."
] | [
"Sumitomo Pharma America, Inc."
] | [
[
{
"name": "็้
ธ้ฒๆ่ฅฟ้
ฎ",
"lang": "CN"
},
{
"name": "Lurasidone Hydrochloride",
"lang": "EN"
},
{
"name": "ใซใฉใทใใณๅกฉ้
ธๅกฉ",
"lang": "JP"
}
]
] | null |
NCT05231044 | [
{
"id_field": "org_study_id",
"id_value": [
"B21-301"
]
}
] | https://clinicaltrials.gov/study/NCT05231044 | A Multi-Center Study to Evaluate the Efficacy and Safety of KX01 Ointment 1% on Actinic Keratosis on Face or Scalp | This Phase III study is designed to evaluate the efficacy and safety of KX01 Ointment in adult participants when applied to an area of skin containing more than 1, clinically typical Actinic Keratosis (AK) lesions on the face or scalp. | A Phase 3, Double-Blind, Vehicle-Controlled, Randomized, Parallel Group, Multicenter, Efficacy, Safety and PK Study of KX01 Ointment 1% in Japanese Adult Subjects With Actinic Keratosis on the Face or Scalp | [
{
"description": "The experimental drug, KX01 Ointment 1% is used in participants with Clinically typical AK on the face or scalp.",
"name": "KX01 ointment 1%",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Vehicle Ointment is used in participants... | [
{
"design_group_description": "KX01 Ointment 1% is applied topically once daily for 5 consecutive days on face or scalp",
"design_group_title": "KX01 Ointment 1%",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
... | [
"Actinic Keratosis"
] | [
"PharmaEssentia Corp."
] | [
"PharmaEssentia Japan KK"
] | [
[
{
"name": "็น็ญๅธๆ",
"lang": "CN"
},
{
"name": "Tirbanibulin",
"lang": "EN"
}
]
] | null |
NCT00002836 | [
{
"id_field": "org_study_id",
"id_value": [
"DM95-047"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"P30CA016672"
]
},
{
"id_domain": "UT MD Anderson Cancer Center",
"id_field": "secondary_id",
"id_type": "Other Id... | https://clinicaltrials.gov/study/NCT00002836 | Filgrastim Plus Chemotherapy Compared With Filgrastim Alone In Treating Women Undergoing Peripheral Stem Cell Transplantation For Breast Cancer | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of ch... | A Phase III Randomized Comparison of High Dose Chemotherapy G-CSF To G-CSF For Mobilization of Peripheral Blood Stem Cells For Autologous Transplantation For Patients With Responsive Metastatic Breast Cancer Or High Risk Stage II-III Patients | [
{
"description": "For group one (Filgrastim + Chemotherapy), given under the skin (SC) on day 4 every 12 hours until completion of apheresis; for group two (Filgrastim alone), beginning on day of reinfusion twice a day (bid) until white blood count (WBC) reaches a safe level.",
"name": "Filgrastim (G-CSF)",... | [
{
"design_group_title": "Filgrastim + Chemotherapy",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "For group one (Filgrastim + Chemotherapy), given under the skin (SC) on day ... | [
"Breast Cancer"
] | [
"The University of Texas MD Anderson Cancer Center"
] | [
"National Cancer Institute"
] | [
[
{
"name": "ไพๆๆณ่ท",
"lang": "CN"
},
{
"name": "Etoposide",
"lang": "EN"
},
{
"name": "ใจใใใทใ",
"lang": "JP"
}
],
[
{
"name": "็ฏ็ฃท้
ฐ่บ",
"lang": "CN"
},
{
"name": "Cyclophosphamide",
"lang": "EN"
},
{
"name"... | null |
NCT00688376 | [
{
"id_field": "org_study_id",
"id_value": [
"E2020-G000-333"
]
},
{
"id_domain": "NCT00687635",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"E2020-G000-334"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
... | https://clinicaltrials.gov/study/NCT00688376 | Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment | The purpose of this study is to evaluate the efficacy, safety and tolerability of donepezil in children with persistent attention impairment that is present at least 12 months after the completion of cancer treatment. | Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment | [
{
"description": "During the 12-week Double-Blind Phase, subjects will receive oral donepezil hydrochloride tablets starting at a dose of 3 mg once daily. Doses will be increased incrementally at successive 3-week intervals on the basis of weight and tolerability. The final daily dose will be 3, 5, or 10 mg dep... | [
{
"design_group_title": "1",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "During the 12-week Double-Blind Phase, subjects will receive oral donepezil hydrochloride tablets st... | [
"Attention Impairment"
] | [
"Eisai, Inc."
] | [
"Eisai Co., Ltd."
] | [
[
{
"name": "็้
ธๅคๅฅๅ้ฝ",
"lang": "CN"
},
{
"name": "Donepezil Hydrochloride",
"lang": "EN"
},
{
"name": "ใใใใธใซๅกฉ้
ธๅกฉ",
"lang": "JP"
}
]
] | null |
NCT04098666 | [
{
"id_field": "org_study_id",
"id_value": [
"AAAS6912"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01AG062624"
]
},
{
"id_field": "acronym",
"id_value": [
"MAP"
]
}
] | https://clinicaltrials.gov/study/NCT04098666 | Metformin in Alzheimer's Dementia Prevention | MAP will be a multisite phase II/III 1:1 randomized controlled trial (RCT) of long acting metformin (reduced mass Glucophage XR) vs. matching placebo in 326 men and women with early and late aMCI, without diabetes, not treated with metformin, overweight or obese, aged 55 years to 90 years. The RCT will last 18 months a... | Metformin in Alzheimer's Dementia Prevention | [
{
"description": "Placebo tablet identical to metformin, up to 4 tablets a day",
"name": "Placebo oral tablet",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Placebo"
],
"type": "Drug"
},
{
"description": "Metformin extended release 500 mg tablets, up ... | [
{
"design_group_description": "Extended release metformin 500 mg tablets up to 2,000 mg (4 tablets) a day once at night. The maximum dose will be attempted during a titration period in the first month of the study.",
"design_group_title": "metformin users",
"design_group_type": "Experimental",
"desi... | [
"Mild Cognitive Impairment"
] | [
"Columbia University"
] | [
"Boston University",
"The University of Texas Southwestern Medical Center",
"State University of New York at Buffalo",
"The University of New Mexico",
"Eastern Virginia Medical School",
"Medical College of Wisconsin",
"Stanford University",
"Pennington Biomedical Research Center",
"National Institut... | [
[
{
"name": "ไบ็ฒๅ่",
"lang": "CN"
},
{
"name": "Metformin",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "MAP"
}
] |
NCT02176460 | [
{
"id_field": "org_study_id",
"id_value": [
"COL-01"
]
}
] | https://clinicaltrials.gov/study/NCT02176460 | Colchicine for Symptom and Inflammation in Knee Osteoarthritis | Uric acid may be involved in the activation of the innate immune response in osteoarthritis (OA) pathology and progression. This suggests that traditional gout therapy may be beneficial for OA. Our goal therefore is to assess colchicine, an existing commercially available agent for gout, for a new therapeutic indicatio... | A Randomized Controlled Trial of Colchicine for Symptom and Inflammation Modification in Knee Osteoarthritis | [
{
"description": "0.5mg twice daily for 16 weeks",
"name": "Colchicine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"generic colchicine tablets (SIN 12490P)"
],
"type": "Drug"
},
{
"description": "1 tablet twice daily",
"name": "Placebo",
"no... | [
{
"design_group_description": "0.5mg twice daily for 16 weeks",
"design_group_title": "colchicine",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "0.5mg twice daily for 16 ... | [
"Knee Osteoarthritis"
] | [
"Singapore General Hospital Pte Ltd."
] | [
"Duke-NUS Graduate Medical School Singapore",
"Duke University"
] | [
[
{
"name": "็งๆฐดไป็ขฑ",
"lang": "CN"
},
{
"name": "Colchicine",
"lang": "EN"
},
{
"name": "ใณใซใใใณ",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"code": "de54ae25e223aa52825ee22a82eea0dd",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "COLKOA"
}
] |
NCT00524849 | [
{
"id_field": "org_study_id",
"id_value": [
"CZOL446ECN05"
]
}
] | https://clinicaltrials.gov/study/NCT00524849 | Zometa and Circulating Vascular Endothelial Growth Factor (VEGF) in Breast Cancer Patients With Bone Metastasis | The primary objective of this study is to evaluate the effects of Zometa (zoledronic acid, 1 mg per week versus 4 mg every four weeks) on the circulating vascular endothelial growth factor (VEGF) levels in breast cancer patients with bone metastases. Sixty patients will be randomized into two groups. | Randomized Phase 2 Study on the Relationship Between Circulating VEGF and Weekly or Every-four-week Zometa in Breast Cancer Patients With Bone Metastases | [
{
"description": "Zometa 1 mg weekly (intravenous)",
"name": "Zoledronic acid",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"Zometa"
],
"type": "Biological"
},
{
"description": "Zometa 4 mg every four weeks (intravenous)",
"name": "Zoledronic acid... | [
{
"design_group_description": "Zometa 4mg IV q4w, in combination with other antitumor agents one month after the initial dosing.",
"design_group_title": "conventional Zometa",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"interv... | [
"Metastatic Breast Cancer",
"Bone Metastases"
] | [
"Fudan University"
] | [
"Novartis AG"
] | [
[
{
"name": "ๅๆฅ่ฆ้
ธ",
"lang": "CN"
},
{
"name": "Zoledronic Acid",
"lang": "EN"
},
{
"name": "ใพใฌใใญใณ้
ธๆฐดๅ็ฉ",
"lang": "JP"
}
]
] | null |
NCT00725270 | [
{
"id_field": "org_study_id",
"id_value": [
"SU-06012008-1191"
]
},
{
"id_field": "secondary_id",
"id_value": [
"76458"
]
}
] | https://clinicaltrials.gov/study/NCT00725270 | Treatment of Schizoaffective Disorder Using Mifepristone | This study tests the hypothesis that mifepristone will diminish cognitive distortion and alleviate psychosis in patients with schizoaffective disorder. | Treatment of Schizoaffective Disorder Using Mifepristone | [
{
"description": "600 mg of mifepristone",
"name": "Mifepristone",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Placebo comparator",
"name": "Placebo Oral Tablet",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
... | [
{
"design_group_description": "Patients will be randomized to placebo",
"design_group_title": "Placebo",
"design_group_type": "Placebo Comparator",
"design_group_type_normalized_id": "20d1ebb7d90a3d9b81daa54f73163ecb",
"intervention": [
{
"intervention_description": "Placebo compar... | [
"Psychotic Disorders",
"Depressive Disorder, Major",
"Depressive Disorder"
] | [
"Stanford University"
] | [
"Pritzker Family Foundation"
] | [
[
{
"name": "็ฑณ้ๅธ้
ฎ",
"lang": "CN"
},
{
"name": "Mifepristone",
"lang": "EN"
},
{
"name": "ใใฝใใญในใใผใซ",
"lang": "JP"
}
]
] | null |
NCT00973349 | [
{
"id_field": "org_study_id",
"id_value": [
"V112_01"
]
}
] | https://clinicaltrials.gov/study/NCT00973349 | Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly Adults | This study will evaluate the safety and immunogenicity of different combinations of A/H1N1 S-OIV (swine flu) vaccine in non-elderly and elderly adults. | A Pivotal Randomized, Single-Blind, Dose-Finding Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of an Adjuvanted and Non-Adjuvanted Egg-Derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Adult Subjects 18 or More Years of Age | [
{
"description": "8 arms consisting of different antigen combinations of A/H1N1 S-OIV and different percentages of MF59 adjuvant",
"name": "MF59-eH1N1_f",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
}
] | [
{
"design_group_description": "50% of MF59 with 3.75 ยตg A/H1N1 antigen",
"design_group_title": "3.75_(50)MF59",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "8 arms consis... | [
"Influenza"
] | [
"Novartis AG"
] | [
"Novartis Vaccines & Diagnostics, Inc."
] | [
[
{
"name": "Influenza vaccine(Seqirus GmbH)",
"lang": "EN"
}
]
] | null |
End of preview. Expand in Data Studio
๐ฅ Dataset Summary
Structured clinical trial records sourced from ClinicalTrials.gov. Each record extracts and normalizes key parameters including study purpose, intervention arms, trial conditions, and sponsor/collaborator relationships. Drug entities are enriched with multilingual name mappings (Chinese, English, Japanese).
๐ Key Features
- Structured Intervention Arms:
arm_interventioncaptures each trial arm's design group type, linked interventions, and single/multi-drug configuration. - Multilingual Drug Entities:
experimental_drugprovides normalized drug names in CN/EN/JP for cross-lingual applications. - Condition & Sponsor Mapping:
f_conditiontags diseases/conditions;sponsorandcollaboratormap the organizational network behind each trial. - Registry Linkage: Full ClinicalTrials.gov URL and secondary IDs (NIH grant numbers, org study IDs, acronyms) for traceability.
๐ Resources
- Developer Portal: open.patsnap.com
- PatSnap Life Sciences: patsnap.com/solutions/life-sciences
- GitHub: github.com/patsnap
- Downloads last month
- 56